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The LXR-regulated E3 ubiquitin ligase IDOL controls
LDLR receptor stability independent of SREBP and
PCSK9, but its relevance to plasma lipid levels is un-
known. Here we demonstrate that the effects of the
LXR–IDOL axis are both tissue and species specific.
In mice, LXR agonist induces Idol transcript levels
in peripheral tissues but not in liver, and does not
changeplasmaLDL levels.Accordingly, Idol-deficient
mice exhibit elevated LDLR protein levels in periph-
eral tissues, but not in the liver. By contrast, LXR acti-
vation in cynomolgus monkeys induces hepatic IDOL
expression, reduces LDLR protein levels, and raises
plasma LDL levels. Knockdown of IDOL in monkeys
with an antisense oligonucleotide blunts the effect of
LXR agonist on LDL levels. These results implicate
IDOL as amodulator of plasma lipid levels in primates
and support further investigation into IDOL inhibition
as a potential strategy for LDL lowering in humans.
INTRODUCTION
Coronary heart disease is the leading cause of death in the
industrialized world, and elevated plasma cholesterol levels are
one of its major causes. Despite the efficacy of statin drugs in
lowering LDL cholesterol levels and decreasing CVD risk, addi-
tional therapeutics strategies are needed. Sterol homeostasis
in animals is governed through the coordinate actions of two
sterol-sensing transcription factors, the liver X receptors (LXRs)
and the sterol regulatory element binding proteins (SREBPs)
(Brown and Goldstein, 1997; Peet et al., 1998).
The LXRs control the expression of a battery of genes involved
in the uptake, transport, efflux, and excretion of cholesterol in a
tissue-specific manner. In addition, in the setting of cellular910 Cell Metabolism 20, 910–918, November 4, 2014 ª2014 Elseviercholesterol excess, LXRs limit the uptake of cellular cholesterol
through transcriptional induction of the gene encoding the
E3 ubiquitin ligase, the inducible degrader of the LDLR (IDOL)
(Zelcer et al., 2009). IDOL binds directly to the cytoplasmic tail
of the LDLR and promotes its ubiquitination by the UBE2D1/E1
complex (Calkin et al., 2011; Zhang et al., 2011). This ubiquiti-
nated LDLR then enters the MVB protein-sorting pathway and
is shuttled to the lysosome for degradation (Scotti et al., 2011;
Sorrentino et al., 2013b).
Previous work showed the acute hepatic overexpression of
Idol in mice reduces LDLR protein levels and increases plasma
cholesterol levels (Zelcer et al., 2009). Furthermore, targeted
deletion of IDOL in cultured mouse cells leads to increased
LDLR protein levels and increased LDL uptake, and this increase
is additive with the effect of statin treatment (Scotti et al., 2011).
However, treatment of mice with an LXR agonist does not raise
plasma LDL levels (Grefhorst et al., 2002), raising the question
of the physiological impact of the LXR-Idol pathway in the liver.
The effect of loss of IDOL function on plasma cholesterol levels
is currently unknown. Thus, it is unclear whether IDOL might
be a suitable target for a new class of lipid-lowering drugs.
Herewedemonstrate that the effects of the LXR-IDOLpathway
on LDLR protein levels are both tissue and species specific. In
mice, hepatic LDLR protein is relatively resistant to LXR agonists
or loss of IDOL activity. By contrast, LXR agonists raise plasma
LDL cholesterol levels in primates through an IDOL-dependent
mechanism. These observations support further investigation of
the LXR–IDOLpathway as a potential therapeutic target and sug-
gest that IDOL inhibition maymitigate undesirable effects of syn-
thetic LXR agonists on plasma LDL cholesterol levels in humans.RESULTS
Tissue-Specific Regulation of LDLR Protein by the
LXR-IDOL Pathway in Mice
Previous work demonstrated that mouse embryonic stem cells
lacking IDOL expression had increased basal LDLR proteinInc.
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agonists (Scotti et al., 2011, 2013). To determine the conse-
quences of loss of IDOL expression for cholesterol homeostasis
in vivo, we generated global IDOL-deficient mice. Analysis of
mRNA expression in Idol–/– mice confirmed an absence of Idol
transcripts and showed no significant change in the expression
of a battery of other genes linked to cholesterol metabolism,
including LDLR, PCSK9, and HMGCR (Figure 1A). We observed
no difference in total or LDL cholesterol levels in the plasma be-
tween chow-fed wild-type (WT) and Idol–/– mice (Figure 1C and
Figure S1A, available online). Also, we did not detect any signif-
icant changes in plasma apolipoprotein B levels in Idol–/– mice
(data not shown). Treatment of Idol–/– mice with synthetic LXR
agonist did not change hepatic LDLR protein or plasma LDL
levels (Figures 1B and S1B). Feeding a high-cholesterol western
diet for 12 months uncovered a subtle but reproducible increase
in hepatic LDLR protein levels in Idol–/– mice (Figure 1E). This
was associated with a trend toward reduced plasma cholesterol
levels that did not reach statistical significance (Figures 1F
and 1G).
In contrast to the liver findings, the basal levels of LDLR protein
were much higher in heart, spleen, and macrophages of Idol–/–
mice than in those of WT mice (Figures 1B and 1D). We have
also observed increased LDLR expression in a number of other
peripheral tissues from Idol–/– mice (data not shown). Further-
more, LXR agonist treatment reduced LDLR protein levels in
heart, spleen, and macrophages of WT but not Idol–/– mice.
This effect correlated with induction of protein levels of
ABCA1, an established LXR target.
Activity of the Hepatic LXR-IDOL Pathway Is Species
Specific
Species-specific differences in lipid metabolism are common. In
the case of LXR, several differences between mouse and human
gene regulation have been described. For example, Cyp7A1 is a
target of LXRs in mice but not humans, and the CETP gene is an
LXR target that is not present in mice (Honzumi et al., 2010; Luo
and Tall, 2000; Repa et al., 2000). To address the possibility of a
species-specific regulation of IDOL, we compared the activity of
the LXR–IDOL pathway in mice, humans, and cynomolgus mon-
keys. An LXR agonist induced IDOLmRNA expression in sterol-
starved hepatocytes from all species (Figure 2A). To examine the
functional consequences of this observation, LDL uptake studies
were performed. LXR agonist treatment blocked LDL uptake in
mouse macrophages and human HepG2 hepatoma cells, but
not in mouse hepatocytes (Figures 2B and S2A–S2C). Consis-
tent with these differences in lipid uptake, synthetic and sterol
LXR agonists caused degradation of the LDLR only in monkey
hepatocytes and human hepatoma cells (Figures 2C–2E and
S2D). Interestingly, we were able to detect endogenous IDOL
protein in human but not mouse hepatocytes using a validated
monoclonal antibody that recognizes both mouse and human
proteins (Scotti et al., 2013) (Figure 2D and data not shown).
Importantly, knockdown of IDOL with siRNA reduced IDOL
protein and LDLR degradation as expected in HepG2 cells (Fig-
ure 2D). These data demonstrate that the effects of the LXR–
IDOL pathway on the LDLR are both tissue and species specific.
One important difference between mouse and primate cells
is the ability of LXRs to induce expression of the LXRa gene inCell Mresponse to ligand activation in primates but not mice (Laffitte
et al., 2001). We hypothesized that this species-specific feedfor-
ward mechanism might allow certain LXR target genes to be
more responsive to LXR pathway activation in humans and
nonhuman primates compared to mice. In support of this hy-
pothesis, blocking the autoregulation of LXRa expression in
HepG2 cells with siRNAs blunted the ability of LXR agonists to
induce the degradation of the LDLR (Figure 2F).
The LXR-IDOL Axis Is Active in Nonhuman Primates
To address whether LXR activation might have different conse-
quences for hepatic LDLR protein levels in mice and primates,
we treated high-fat-diet-fed cynomolgus monkeys with a syn-
thetic LXR agonist. GW3965 treatment for 7 days led to marked
increases in total cholesterol and LDL cholesterol levels with no
changes in HDL or VLDL cholesterol levels (Figures 3A and S3A).
Plasma apolipoprotein B-100 levels were increased (Figure 3B).
Hepatic cholesterol levels were not different between groups
(Figure S3B). Plasma triglyceride levels were also not different
(Figure S3C), although there was a trend toward increased he-
patic triglyceride content with GW3965 treatment (Figure S3B).
Genome-wide transcriptional profiling of hepatic gene expres-
sion confirmed the induction of multiple LXR target genes in
response to GW3965 treatment (Figure 3C). In contrast to the
findings in mouse liver in vivo (Figure 1), LXR activation substan-
tially induced IDOLmRNA expression inmonkey liver in vivo (Fig-
ure 3D). mRNAs encoding the established LXR targets ABCA1
and SREBP-1c were also induced by LXR agonist in parallel.
Consistent with increased IDOL expression and higher plasma
LDL levels, hepatic LDLR protein levels were reduced in
GW3965-treated monkeys (Figure 3E). There was no change
in LDLR or HMCGR transcript levels in response to LXR activa-
tion, strongly suggesting that the observed changes stemmed
from IDOL-mediated posttranscriptional effects (Figure 3D and
data not shown). We also found no effect of GW3965 treatment
on plasma PCSK9 protein levels in cynomolgus monkeys
(Figure 3F).
IDOL Contributes to the Effect of LXR Agonists on
Plasma LDL Cholesterol
To definitively address the involvement of IDOL in the effects of
LXR agonists on plasma lipid levels in cynomolgus monkeys, we
generated and characterized high-affinity, generation 2.5 anti-
sense oligonucleotides (ASOs). We identified two ASOs that
significantly reduced IDOL mRNA levels in human Huh-7 cells,
human Hep3B cells, and primary monkey hepatocytes (Fig-
ure S4A). Furthermore, when HepG2 cells were cultured in full
serum-containing (sterol-rich) media (conditions under which
the LXR-IDOL pathway is active), IDOL ASO treatment raised
LDLR protein levels (Figure 4A). When HepG2 cells were cultured
in sterol-deficient media (conditions under which the endoge-
nous LXR pathway is inactive and LDLR ismaximally expressed),
IDOL ASO-treatment blocked the ability of synthetic LXR agonist
to stimulate LDLR degradation (Figure 4B). Note that IDOL ASOs
would not be expected to raise basal LDLR expression in sterol-
deficient media because IDOL is not expressed in the absence of
LXR agonist.
In vivo studies in a cohort of cynomolgus monkeys (n = 4/
group) confirmed the ability of IDOL ASOs to reduce hepaticetabolism 20, 910–918, November 4, 2014 ª2014 Elsevier Inc. 911
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Figure 1. IDOL Controls Peripheral LDLR Expression in Mice
WT and Idol null mice were treated with the LXR agonist GW3965 at 40 mg/kg for 3 days (n = 3–4/group).
(A) Hepatic gene expression was quantified by real-time PCR and normalized to 36B4.
(B) Protein lysates from liver, heart, and spleen were analyzed by immunoblotting with antibodies against ABCA1, LDLR, and b-actin. (n = 3–4 mice/treatment).
(C) Total serum cholesterol and triglyceride levels for chow-fed animals.
(D) Immunoblot analysis of protein extracts from thioglycollate-elicited peritoneal macrophages isolated from WT and Idol null mice and treated with GW3965
(1 mM). Immunoblot shown is representative of three independent experiments.
(legend continued on next page)
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Figure 2. Species-Specific Regulation of
Hepatic LDLR Protein Expression by the
LXR–IDOL Pathway
Primary hepatocytes from mice, humans, and
nonhuman primates were serum starved and
treated with GW3965 (1 mM) for 24 hr.
(A) Regulation of IDOL mRNA expression by LXR
agonists.
(B) Quantification of cellular uptake of DiI-LDL
uptake in the presence or absence of GW3965.
Cell-associated fluorescencewasmeasuredwith a
Typhoon Instrument. n = 3. ***p < 0.001.
(C and D) Immunoblot analysis of protein lysates
from primary mouse hepatocytes (C) or human
HepG2 cells (D) treated with GW3965 (1 mM) for
24 hr.
(E) Immunoblotting of protein lysates from cyn-
omolgus monkey hepatocytes treated with
GW3965 (1mM)or 22R-hydroxycholesterol (2.5mM)
for 24 hr.
(F) Immunoblot analysis of protein lysates from
control or LXRa-siRNA-transfected HepG2 cells
treated for 24 hr with increasing doses of GW3965.
Data are representative of three independent
experiments. Error bars represent SEM.
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The LXR-IDOL Axis Regulates LDL Levels in PrimatesIDOL mRNA expression (Figures S4B and 4C). There was also a
trend toward lower total plasma cholesterol and plasma LDL
cholesterol levels in the animals receiving IDOL ASOs (Figures
4D and S4C). HDL cholesterol levels were not different between
groups (Figure S4C).
To test the ability of IDOL inhibition to affect LXR-dependent
changes in plasma cholesterol levels, we conducted a study
on a larger cohort of high-fat-diet-fed monkeys (study design is
shown in Figure 4E). The animals were treated for 9 weeks with
vehicle or the IDOL ASO (n = 8/group). During the ninth week,
all of the animals were administered GW3965 to activate the
LXR–IDOL pathway. No overt hepatotoxicity was observed in
response to IDOL ASO administration as assessed by plasma
AST and ALT levels (Figure S4D). The IDOL ASO led to a partial
(45%–50%) reduction in IDOL mRNA expression in the liver
(Figure 4F). This partial IDOL knockdown was associated with
a blunted effect of the LXR agonist on plasma LDL cholesterol
levels on day 7 of treatment (Figures 4G–4I). There was substan-(E)WT and Idol null micewere fedwestern diet for 12months. Protein lysates from liver were analyzed by imm
genotype). Significance was determined by Student’s t test (*p < 0.05).
(F) Total serum cholesterol and triglyceride levels for the animals shown in (E).
(G) Plasma lipoprotein cholesterol distribution for the animals shown in (E). Error bars represent SEM.
Cell Metabolism 20, 910–918,tial variability in the individual plasma LDL
cholesterol values, prompting us to eval-
uate the effect of LXR agonist treatment
for each individual animal (Figure 4H).
Although the difference in average plasma
LDL cholesterol levels between groups
did not reach statistical significance, the
average percent change in LDL choles-
terol for each individual in response to
LXR agonist was significantly different
(p < 0.05) (Figure 4G). Moreover, thechange in LDL cholesterol and total cholesterol in response to
GW3965 over the entire course of LXR agonist treatment (day
3, 5, and 7) was also significantly different between vehicle and
IDOL ASO-treated animals (Figure 4I). Plasma and hepatic tri-
glyceride levels, and hepatic cholesterol levels, were not signifi-
cantly different between groups (Figures 4G and S4E). HPLC
analysis of plasma cholesterol distributions at the beginning
and at the end of the study (pretreatment baseline versus day
7 GW treatment) revealed a smaller change from baseline in
the IDOL-ASO group in both the LDL and VLDL fractions. There
was no change in hepaticmRNA expression of LDLR or HMGCR,
suggesting that IDOL inhibition can modulate plasma LDL levels
independent of those parameters (Figure 4F).
DISCUSSION
We have shown here that regulation of IDOL expression by the
LXR signaling pathway has distinct consequences for plasmaunoblotting and quantified using ImageJ (n = 7mice/
November 4, 2014 ª2014 Elsevier Inc. 913
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Figure 3. LXR Activation in Nonhuman Primates Reduces Hepatic LDLR Protein and Raises Plasma LDL Levels
(A) Plasma lipoprotein cholesterol distribution of cynomolgus monkeys treated with vehicle or GW3965 (10 mg/kg for 7 days) (n = 5 pooled samples/group).
(B) Plasma apolipoprotein (apoB-100, apoE, and apoA-I) distributions for animals shown in (A).
(C) Transcriptional profiling of mRNA from the livers of cynomolgus monkeys treated for 2 days with vehicle or GW3965. Tissues were obtained 6 hr after the last
dose, and transcript levels were analyzed with Affymetrix arrays.
(D) Hepatic gene expression from the animals in (C) as determined by real-time PCR; BP-1C = SREBP-1c (n = 5/group; **p < 0.01).
(E) Protein lysates of the liver from cynomolgus monkeys treated with vehicle or GW3965 (10 mg/kg for 7 days). Tissues were obtained 24 hr after the final dose;
immunoblots were performed for LDLR, ABCA1, and tubulin.
(F) ELISA of plasma levels of PCSK9 in cynomolgus monkeys treated with vehicle or GW3965 (10 mg/kg for 7 days) (n = 5/group). Error bars represent SEM.
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of LXR more strongly induces hepatic IDOL expression in pri-
mates compared to mice. As a consequence, LXR agonists raise
plasma LDL levels in primates, but not mice. These results have
implications for our understanding of the role of LXR nuclear re-
ceptors in orchestrating lipid homeostasis as well as the ongoing
effort to target LXR or its downstream effectors in human
disease.
Murine models can be valuable tools for the development of
new drug strategies. However, differences in hepatic lipid meta-914 Cell Metabolism 20, 910–918, November 4, 2014 ª2014 Elsevierbolism between mice and primates complicate the use of mice
as models for human therapeutics. In the case of the LXR–
IDOL pathway, the study of mice was not predictive of the in vivo
relevance of this pathway in primates. The fact that mice carry
most of their cholesterol on HDL makes it difficult to assess
LDL metabolism in this model without dietary or genetic manip-
ulations. In the future, it will be interesting to examine the poten-
tial effect of increased peripheral LDLR expression in a more
humanized mouse model, such as CETP transgenic mice (Agel-
lon et al., 1991). Furthermore, although our data indicate that theInc.
Cell Metabolism
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activity in mouse liver, IDOL clearly affects LDLR protein levels in
a number of peripheral tissues. The question of whether altered
IDOL target expression in peripheral tissues can influence
cellular or systemic cholesterol metabolism will be an interesting
one for future investigation.
Genome-wide association studies have linked polymorphisms
at the IDOL locus to plasma LDL cholesterol levels in humans
(Chasman et al., 2012; Teslovich et al., 2010; Weissglas-
Volkov et al., 2011). Most recently, individuals with a complete
loss-of-function mutation in the IDOL gene were identified and
shown to have reduced levels of LDL cholesterol, suggestive
of increased LDLR-dependent LDL clearance (Sorrentino et al.,
2013a). Our results help to explain why genome-wide associa-
tion studies have linked variation in the IDOL locus with changes
in human plasma lipid levels, despite the low activity of the
LXR-IDOL pathway in mouse liver.
Synthetic LXR agonists are powerful regulators of reverse
cholesterol transport that inhibit the development of atheroscle-
rosis in mice (Naik et al., 2006; Tangirala et al., 2002). The devel-
opment of LXR agonists as therapeutics, however, has been
hampered by the induction of hepatic lipogenesis, an undesir-
able side effect of LXR agonists. Our results identify elevation
of plasma LDL cholesterol levels as an additional unexpected
complication of systemic LXR agonism in primates. Importantly,
this effect was not predicted from preclinical studies in rodents
due to the species-specific differences in hepatic activity of the
LXR-IDOL pathway.
Three pathways are known to exert a strong influence on LDLR
expression: SREBP, PCSK9, and IDOL (Abifadel et al., 2003;
Brown and Goldstein, 1986; Cohen et al., 2005; Zelcer et al.,
2009). Statins, which act indirectly through SREBP, and anti-
bodies directed against PCSK9, which are in late-stage clinical
development, increase LDLR (Stein and Raal, 2014; Young and
Fong, 2012). As an independent mechanism for regulation of
the LDLR, the LXR–IDOL pathway could represent a potential
target for the development of a new class of lipid-lowering drugs.
Interestingly, statins have additive effects with IDOL inhibition on
LDLR expression in cells (Scotti et al., 2011).
Our results establish that changing the activity of the LXR–
IDOL pathway in nonhuman primates changes LDLR protein
expression and plasma LDL levels. An unresolved issue at this
stage is whether IDOL inhibition would be predicted to lower
plasma LDL cholesterol in humans in the absence of LXR activa-
tion. Although there was a trend for reduction in cholesterol
levels in response to IDOL ASOs (Figure 4D), the high variability
in plasma lipids in our cohorts, as well as the modest degree of
knockdown of IDOL expression by our ASOs (Figure 4F), pre-
vents us from being able to answer the question at this time.
Given the variability in plasma LDL levels in our ASO study, it
would have been interesting to assess LDLR protein levels in in-
dividual animals before and after ASO treatment. Unfortunately,
pretreatment liver biopsies were not obtained under the current
experimental protocol. Nevertheless, these observations sup-
port further investigation of the LXR–IDOL pathway as a potential
target for the modulation of LDL cholesterol levels. Our results
further suggest that IDOL inhibition may mitigate undesirable
effects of synthetic LXR agonists on plasma LDL cholesterol
levels in humans.Cell MEXPERIMENTAL PROCEDURES
Cell Culture and LXR Agonists
The LXR agonists GW3965 and T0901317 were synthesized as described
(Collins et al., 2002a; Collins et al., 2002b; Li et al., 2000). Primary peritoneal
macrophages were collected 4 days after thioglycollate injection (Hong
et al., 2011). Primary murine hepatocytes were collected as described (Rong
et al., 2013). Human and nonhuman primate primary hepatocytes were pur-
chased from Corning and Life Technologies. Cells were placed in 0.5% serum
or 10% LPDS supplemented with 5 mM simvastatin plus 100 mM mevalonic
acid for 5 hr and then treated overnight with GW3965. ASOs were transfected
using Lipofectamine or FUGENE 9. siOligos targeting human LXRa or control
were purchased from ThermoScientific and transfected using Dharmafect 4.
RNA Analysis
Total RNA was isolated from tissues using TRIzol (Invitrogen) reverse tran-
scribed with random hexamers with the Taqman Reverse Transcription Re-
agents Kit (Applied Biosystems). Real-time quantitative PCR assays were
performed using an Applied Biosystems 7900HT sequence detector. For hu-
man and mouse experiments, Sybergreen (Diagenode) was used. Gene-spe-
cific Applied Biosystems Taqman assays and iTaq were used to quantify
nonhuman primate gene expression. Results show averages of duplicate ex-
periments normalized to 36B4 or Gapdh. The primer sequences and Taqman
assay IDs are available upon request. The microarray profiling studies were
performedwith Affymetrix Human U133 Plus 2.0 Array chips by the UCLA Clin-
ical Microarray Core (GEO accession number GSE61381).
Antibodies and Immunoblots
Total cell lysates were prepared in RIPA buffer supplemented with protease in-
hibitors (Roche Molecular Biochemicals) and PMSF. Samples (10–40 mg) were
separated on NuPAGE Bis-Tris gels (Invitrogen) and transferred to nitrocellu-
lose. Membranes were probed with the following antibodies: LDLR (1:1,000;
Cayman Chemical or AbCam), ABCA1 (1:1,000; Novus), actin (1:10,000;
Sigma), and tubulin (1:3000 Calbiochem). Horseradish peroxidase (HRP)-con-
jugated secondary antibodies (Zymed) were used, and antibody binding was
visualized by chemiluminescence (ECL Plus GE Healthcare). Blots were quan-
tified by densitometry with ImageJ software (version 1.42q; National Institutes
of Health).
Murine Studies
Mice were housed under pathogen-free conditions in a temperature-
controlled room with a 12 hr light/dark cycle. Idol/ mice were generated
through injection of previously described SV129 Idol-targeted ESCs (Scotti
et al., 2011) into C57BL/6 blastocysts. Mice and were studied on a mixed
SV129/C57BL/6 background as well as after backcrossing seven generations
to C57BL/6 mice. Mice were fed a standard chow diet or a western diet
(Research Diets #D12079B). For ligand treatment studies, mice were gavaged
with either vehicle or GW3965 or T0901317 (40mg/kg) daily for 3 days. Tissues
were harvested 6 hr after the last gavage. All mouse experiments were
approved by the UCLA Animal Care and Research Advisory Committee.
Antisense Oligonucleotides
ASOs were designed to target cynomolgus monkey IDOL mRNA (ASO1, ASO
549069, 50-CTCCATGACCATACAA-30; and ASO2, ASO 549127, 50-AAGTT
TAAGTAACCCA-30). ASOs consisted of a chimeric 16-mer phosphorothioate
backbone containing 2-O-methoxyethyl groups at positions 1, 2, and 16 and
2040-constrained ethyl BNAs at positions 3, 14, and 15 targeting cynomolgus
monkey IDOL sequences. The ASOs were synthesized and purified on an
automated DNA synthesizer using phosphoramidite chemistry (Murray et al.,
2012).
Nonhuman Primate Studies
All experiments were approved by the WFUHS Institutional Animal Care and
Use Committee (IACUC). Male cynomolgus were pair-housed when possible
in climate-controlled conditions with 12 hr light/dark cycles. Monkeys
were provided water ad libitum and fed twice a day with high-fat, moderate
cholesterol semisynthetic diet. For the 7 day LXR agonist treatment study,
ten monkeys were fasted overnight, anesthetized with 5 mg/kg ketamineetabolism 20, 910–918, November 4, 2014 ª2014 Elsevier Inc. 915
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Figure 4. IDOL Knockdown Modulates Hepatic LDLR Expression in Nonhuman Primates
(A and B) Immunoblot analysis of HepG2 cells transfected with control or IDOL ASOs. (A) Cells were cultured in full serum. (B) Cells were cultured in sterol-
deficient media containing 5 mM simvastatin plus 100 mM mevalonic and treated for 24 hr with GW3965 (1 mM). Data are representative of three independent
experiments.
(C) Activity of IDOL ASOs in vivo. Cynomolgus monkeys were treated for 8 weeks with vehicle or IDOL ASOs, and hepatic IDOL expression levels were quantified
by real-time PCR. Each bar represents an individual animal.
(D) Plasma LDL cholesterol was measured at the designated time points for animals shown in (C).
(E) Schematic showing the experimental design for evaluating the effects of IDOL ASO treatment on the response to LXR activation in monkeys.
(F) Liver gene expression determined by real-time PCR (n = 8/group). ***p < 0.001.
(legend continued on next page)
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The LXR-IDOL Axis Regulates LDL Levels in Primatesand 0.0075 mg/kg dexmedetomidine, and gavaged with either vehicle (1% hy-
droxypropyl methylcellulose) or 10 mg/kg. The anesthesia was then reversed
with atipamezole (0.075 mg/kg). The treatment regimen was conducted daily
for 7 days. On day 7, fasted monkeys were anesthetized with 25 mg/kg keta-
mine and isoflurane. The sedated monkeys were euthanized by exsanguina-
tion followed by whole-body perfusion with saline, and tissues were isolated.
For the 2 day LXR agonist treatment study, ten monkeys were fasted, anesthe-
tized, and gavaged with either vehicle or 10 mg/kg GW3965. Exactly 6 hr after
dosing on day 2, fasted monkeys were euthanized and tissues collected.
For in vivo validation of the IDOL ASOs, monkeys were fed the high-fat diet
for 9 weeks and subcutaneously injected onceweekly for 9 weeks with vehicle,
20 mg/kg ASO1, or 20 mg/kg ASO2 (n = 4/group). Two days after the ninth
treatment, fasted monkeys were euthanized and tissues collected. For the
combined LXR agonist and ASO treatment study, 16 monkeys were fed
high-fat diet for 4 weeks and subcutaneously injected once during study
week 1 with vehicle or 40 mg/kg ASO2 and once during study weeks 2–9
with vehicle or 30 mg/kg ASO2. Starting on study week 8, monkeys were
fasted overnight, anesthetized as above, and gavaged with 10 mg/kg
GW3965. The treatment regimen was conducted once daily for 8 days. On
the eighth day, fasted monkeys were euthanized exactly 6 hr after dosing,
and tissues were collected.
Lipid and Lipoprotein Analysis
Lipoprotein cholesterol distributions were determined by on-line, high-perfor-
mance gel-filtration chromatography with Infinity Cholesterol reagent (Thermo)
at the Wake Forest University Lipid Core. Plasma total cholesterol and triglyc-
eride were measured using the Cholesterol Reagent Set (Pointe Scientific) and
Triglyceride Reagent and Free Glycerol Reagent (Sigma). Serum levels of
PCSK9 were measured using the Human PCSK9 Quantikine ELISA kit from
R&D Systems. For apolipoprotein analysis, an equal volume of plasma from
each monkey was pooled and separated on a Superose 6 10/300 GL column
(GE Healthcare). Fractions were resolved on SDS-PAGE gels, the proteins
were transferred to a nitrocellulose membrane, and apolipoproteins were de-
tected with goat anti-monkey affinity-purified antibodies.
Statistical Analysis
Statistics were performed using Student’s t test (two groups) or ANOVA (>2
groups), with post hoc tests to compare to the control group. Data are
presented as means ± SEM or means ± SD as indicated and were considered
statistically significant at p < 0.05.
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